Skip to main navigation Skip to search Skip to main content

High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor

  • Alberto Delaidelli
  • , Fares Burwag
  • , Susana Ben-Neriah
  • , Yujin Suk
  • , Taras Shyp
  • , Suzanne Kosteniuk
  • , Christopher Dunham
  • , Sylvia Cheng
  • , Konstantin Okonechnikov
  • , Daniel Schrimpf
  • , Andreas Von Deimling
  • , Benjamin Ellezam
  • , Sébastien Perreault
  • , Sheila Singh
  • , Cynthia Hawkins
  • , Marcel Kool
  • , Stefan M. Pfister
  • , Christian Steidl
  • , Christopher Hughes
  • , Andrey Korshunov
  • Poul H. Sorensen

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

BACKGROUND: While international consensus and the 2021 WHO classification recognize multiple molecular medulloblastoma subgroups, these are difficult to identify in clinical practice utilizing routine approaches. As a result, biology-driven risk stratification and therapy assignment for medulloblastoma remains a major clinical challenge. Here, we report mass spectrometry-based analysis of clinical samples for medulloblastoma subgroup discovery, highlighting a MYC-driven prognostic signature and MYC immunohistochemistry (IHC) as a clinically tractable method for improved risk stratification.

METHODS: We analyzed 56 formalin fixed paraffin embedded (FFPE) medulloblastoma samples by data-independent acquisition mass spectrometry identifying a MYC proteome signature in therapy-resistant group 3 medulloblastoma. We validated MYC IHC prognostic and predictive value across 2 groups of 3/4 medulloblastoma clinical cohorts (n = 362) treated with standard therapies.

RESULTS: After the exclusion of WNT tumors, MYC IHC was an independent predictor of therapy resistance and death [HRs 23.6 and 3.23; 95% confidence interval (CI) 1.04-536.18 and 1.84-5.66; P = .047 and <.001]. Notably, only ~50% of the MYC IHC-positive tumors harbored MYC amplification. Accordingly, cross-validated survival models incorporating MYC IHC outperformed current risk stratification schemes including MYC amplification, and reclassified ~20% of patients into a more appropriate very high-risk category.

CONCLUSIONS: This study provides a high-resolution proteomic dataset that can be used as a reference for future biomarker discovery. Biology-driven clinical trials should consider MYC IHC status in their design. Integration of MYC IHC in classification algorithms for non-WNT tumors could be rapidly adopted on a global scale, independently of advanced but technically challenging molecular profiling techniques.

Original languageEnglish
Pages (from-to)2431-2444
Number of pages14
JournalNeuro-Oncology
Volume27
Issue number9
DOIs
Publication statusPublished - 1 Sept 2025

Keywords

  • FFPE proteomics
  • MYC
  • Medulloblastoma
  • biomarker
  • risk-stratification
  • Prognosis
  • Follow-Up Studies
  • Humans
  • Child, Preschool
  • Drug Resistance, Neoplasm
  • Male
  • Survival Rate
  • Proto-Oncogene Proteins c-myc/metabolism
  • Cerebellar Neoplasms/metabolism
  • Immunohistochemistry/methods
  • Young Adult
  • Adolescent
  • Proteomics/methods
  • Adult
  • Female
  • Biomarkers, Tumor/metabolism
  • Child
  • Medulloblastoma/metabolism

Fingerprint

Dive into the research topics of 'High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor'. Together they form a unique fingerprint.

Cite this